Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in central macular thickness on OCT · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Significant intraocular inflammation at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised intraocular pressure at 1 year at compared with intravitreal steroid (very low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PEM hand function score at 3 years Major outcome group 1 (hand function) (scores between 0 and 77, where 0 represents no impairment in hand function and 77 represents maximum impairment in hand function) · 79 participants (Ullah 2009)
1 finding from 1 review
Correction of MCPJ and PIPJ deformities at 2 weeks Major outcome group 3 (early angular outcomes) · 79 participants (Ullah 2009)
1 finding from 1 review
Hypoaesthesia Major outcome group 5 (adverse effects) · 79 participants (Ullah 2009)
1 finding from 1 review
Recurrence · 93 participants (van Rijssen 2012a)
1 finding from 1 review
Major outcome group 5 (adverse effects)d · 93 participants (van Rijssen 2012a)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DASH hand function score at 3 months Major outcome group 1 (hand function) (scores between 0 and 100, where 0 represents no impairment in hand function and 100 represents maximum impairment in hand function) · 93 participants (van Rijssen 2012a)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major outcome group 3 (early angular outcome)b · 93 participants (van Rijssen 2012a)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomesa · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DASH hand function score at 3 months Major outcome group 1 (hand function) (scores between 0 and 100, where 0 represents no impairment in hand function and 100 represents maximum impairment in hand function) · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
1 finding from 1 review
Recurrence · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found